Authors


Richard Pops

Latest:

National Recovery Month is a Time for Action

With the headlines focused on COVID-19, many may have forgotten about the escalating epidemic of substance use disorder. National Recovery Month is a time to bring this issue back to the top of the agenda, raise awareness, and drive action, writes Richard Pops, CEO of Alkermes.


Ryan Moog

Latest:

Bridging the Health Equity Gap in Clinical Development

The COVID-19 pandemic has exposed global health inequities and is driving life sciences companies to establish strategies and better leverage data to address systemic causes and improve equity in access to healthcare innovations, particularly in clinical trials.


Christopher J. Calhoun

Latest:

Escaping the “Valley of Death:” The Funding Process for Biotechnology Companies

Christopher J. Calhoun pulls back the curtain on the mysterious biotech funding process.


Jessica Jarvis and Daniel Blessing

Latest:

7 Proven Digital Programs to Supercharge Pharma Value Chain This Year

Each program strengthens the pharma value chain, impacting the core areas of clinical development, supply chain, and manufacturing and commercial engagement.


Dorothee Schramm

Latest:

The Growth of International Arbitration in the Life Sciences Sector

In an unpredictable world, international life sciences collaborations can lead to misunderstandings and enforcement challenges, making an effective dispute resolution mechanism an essential risk management tool.


Edward Triebell

Latest:

A New Era in Clinical Trials

Current industry challenges present an opportunity for innovation and the adoption of new solutions, particularly in addressing barriers related to patient recruitment, engagement, and retention.


Sayali Kadam

Latest:

Revitalizing Mature Pharma Brands: 5 Winning Strategies

Strategies that can help maintain and grow your market share. Plus how to adapt to new competitive pressures and evolving customer needs.


Samina Bari

Latest:

A Risk-Reward Reset: Getting Serious About Social Media

As the digital medium poses new threats to brand equity and public safety for pharma, what can drugmakers do to better balance its essential communications benefits with the risks?



Dipak Bhattacharya

Latest:

The Surprising Inefficiency of Field Deployments

Deployments are often built on the concept that growth comes from new prescribers, which may be limiting their success.


David J. Ludlow

Latest:

FDA Inspection and Enforcement Developments During the COVID-19 Pandemic

Mitigating the risks of development, authorization, and marketing for new therapies following "new normal" created by COVID-related violations.


Donovan Quill

Latest:

Patient-First Approach Ensures People With Rare Disorders Receive Better Care and Outcomes

Improving the patient experience for those with orphan diseases through a patient-first approach.


Barry Winn, BioPharm Communications, LLC
Barry Winn, Brand Insights Contributor, VP, Omnichannel Strategy, BioPharm Communications, LLC

Latest:

2021 Will Be Another Transformative Year for Digital Marketing

While COVID-driven challenges remain many, so do the carryover opportunities to redefine HCP engagement and communication.



Dr. Samy Suissa and Dr. Meg Richards

Latest:

Building Effective Real World Evidence Studies to Support New Indications for Established Products

The use of real-world evidence can prevent pharma companies from performing studies based on flawed data.


Alisa Hummings

Latest:

The Agile Future of Medical Information: Meeting 21st-Century Demands for Healthcare

COVID-19 pandemic has accelerated raised expectations for medical information professionals.


Jenna Phillips

Latest:

Operating Models for Successful DOL Engagement

How life sciences companies can design an effective operating model for DOL engagements.


PCI Pharma Services

Latest:

Viable Options: Packaging and Partnering for Successful Storage and Transport of Conventional Cold-Chain Vaccines for Covid-19

***Live: Thursday, February 25, 2021 at 11am EST | 8am PST | 4pm GMT | 5pm CET*** As strategic planning among manufacturers and logistics partners commences, this webinar will serve as a platform to discuss service offerings and explore the most effective possible solutions. *** On demand until Feb. 25, 2022***


Beth Doladee and Neelima Paranjpey

Latest:

Supporting Successful Pharma Leadership with Neuroscience-Based Learning

To effectively lead in today’s unpredictable environment, several major pharma companies are turning to a neuroscience-based learning approach to leadership development.


Patrick Bubach

Latest:

No Half Measures: How Medical Affairs Can Maximize and Measure Value

Education and knowledge transfer must be prioritized for industry to see sizable improvement in medical affairs.


Michel van Harten, MD

Latest:

How to Enhance DEI in Clinical Trials

Integrating DEI strategies into clinical trials is both crucial for advancing biomedical knowledge and for bolstering trust and equitability within underrepresented communities.


Denice Torres

Latest:

Inclusion Check-In: Who are You Giving Your Energy To?

Three simple ways to build trust—by reaching outside your comfort zone.



Jeremy Lovelace

Latest:

Developing Data Literacy with Training Simulations

In order to address data literacy gaps amongst reps and managers, sales trainers are increasingly turning to computer-based business simulation games, writes Jeremy Lovelace.


Gérard Klop

Latest:

Creating Influence and Authority in Value-Based Healthcare

We may be only at the beginning of outcome-measured, value-based healthcare, but this is a chance for pharma organizations to show their mettle as roles are redefined and definitions of ‘value’ are agreed, says Gérard Klop of Vintura.


Steve Steinhubl, MD

Latest:

Getting ‘Personal’ With Vaccine Development

Innovative and continuous remote patient monitoring, along with AI-based predictive analytics, are advancing progress toward replacing the one-size-fits-all, population-driven vaccination model.


Michael Sarshad

Latest:

Investing for Success: Finding the Right Launch Balance

Challenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.



Zachary Kleiman

Latest:

Bringing Data to Life: How Tech-Savvy Life Sciences Companies Can Better Serve the Healthcare Sector

Going beyond traditional market segmentation to understand the technological and data analytics capacity of target customers.


Brian Kwak

Latest:

The JAKs Journey Offers Valuable Lessons for Innovators

Opportunity remains despite regulatory and access obstacles.